S. E. Stanton, S. Adams, and M. L. Disis, Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: a systematic review, JAMA Oncol, vol.2, issue.10, pp.1354-1360, 2016.

C. Denkert, S. Loibl, A. Noske, M. Roller, B. M. Muller et al., Tumorassociated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer, J. Clin. Oncol, vol.28, issue.1, pp.105-113, 2010.

C. Denkert, G. Minckwitz, J. C. Brase, B. V. Sinn, S. Gade et al., Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without Carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers, J. Clin. Oncol, vol.33, issue.9, pp.983-991, 2015.

H. J. Lee, J. J. Lee, I. H. Song, I. A. Park, J. Kang et al., Prognostic and predictive value of nanostring-based immune-related gene signatures in a neoadjuvant setting of triple-negative breast cancer: relationship to tumor-infiltrating lymphocytes, Breast Cancer Res. Treat, vol.151, issue.3, pp.619-627, 2015.

M. V. Dieci, C. Criscitiello, A. Goubar, G. Viale, P. Conte et al., Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study, Ann. Oncol, vol.25, issue.3, pp.611-618, 2014.

S. Loi, S. Dushyanthen, P. A. Beavis, R. Salgado, C. Denkert et al., RAS/ MAPK activation is associated with reduced tumor-Infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors, Clin. Cancer Res, vol.22, issue.6, pp.1499-1509, 2016.

R. Salgado, C. Denkert, S. Demaria, N. Sirtaine, F. Klauschen et al., The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs working group, Ann. Oncol, vol.26, issue.2, pp.259-271, 2014.

S. Hendry, R. Salgado, T. Gevaert, P. A. Russell, T. John et al., Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immuno-oncology biomarkers working group: part 2: TILs in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors, Adv. Anat. Pathol, 2017.

S. Loi, N. Sirtaine, F. Piette, R. Salgado, G. Viale et al., Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98, J. Clin. Oncol, vol.31, issue.7, pp.860-867, 2013.

S. Loi, S. Michiels, R. Salgado, N. Sirtaine, V. Jose et al., Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial, Ann. Oncol, vol.25, issue.8, pp.1544-1550, 2014.

G. Pruneri, M. Lazzeroni, V. Bagnardi, G. B. Tiburzio, N. Rotmensz et al., The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast, Ann. Oncol, vol.28, issue.2, pp.321-328, 2017.

T. M. Prowell and R. Pazdur, Pathological complete response and accelerated drug approval in early breast cancer, N. Engl. J. Med, vol.366, issue.26, pp.2438-2441, 2012.

P. Cortazar, L. Zhang, M. Untch, K. Mehta, J. P. Costantino et al., Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis, Lancet, vol.384, issue.9938, pp.164-172, 2014.

G. Minckwitz, M. Untch, J. U. Blohmer, S. D. Costa, H. Eidtmann et al., Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes, J. Clin. Oncol, vol.30, issue.15, pp.1796-1804, 2012.

Y. Asano, S. Kashiwagi, W. Goto, M. Takada, T. Takashima et al., Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes (TILs) and residual cancer burden (RCB), Proceedings of the 2016 San Antonio Breast Cancer Symposium, 2016.

S. Antonio and . Philadelphia, Abstract nr P2-05, vol.77, 2016.

W. H. Fridman, F. Pages, C. Sautes-fridman, and J. Galon, The immune contexture in human tumours: impact on clinical outcome, Nat. Rev. Cancer, vol.12, issue.4, pp.298-306, 2012.

E. Garcia-martinez, G. L. Gil, A. C. Benito, E. Gonzalez-billalabeitia, M. A. Conesa et al., Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer, Breast Cancer Res, vol.16, issue.6, p.488, 2014.

M. Miyashita, H. Sasano, K. Tamaki, H. Hirakawa, Y. Takahashi et al., Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study, Breast Cancer Res, vol.17, p.124, 2015.

C. Liedtke, C. Mazouni, K. R. Hess, F. Andre, A. Tordai et al., Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer, J. Clin. Oncol, vol.26, issue.8, pp.1275-1281, 2008.

, Breast Cancer NCCN Guidelines Version 2, 2016.

N. Masuda, S. J. Lee, S. Ohtani, Y. H. Im, E. S. Lee et al., Adjuvant capecitabine for breast cancer after preoperative chemotherapy, N. Engl. J. Med, vol.376, issue.22, pp.2147-2159, 2017.

C. Denkert, S. Wienert, A. Poterie, S. Loibl, J. Budczies et al., Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group, Mod. Pathol, vol.29, issue.10, pp.1155-1164, 2016.

E. Provenzano, V. Bossuyt, G. Viale, D. Cameron, S. Badve et al., Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group, Mod. Pathol, vol.28, issue.9, pp.1185-1201, 2015.

R. Salgado, C. Denkert, C. Campbell, P. Savas, P. Nuciforo et al., Tumorinfiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial, JAMA Oncol, vol.1, issue.4, pp.448-454, 2015.

C. Denkert, G. Minckwitz, S. Darb-esfahani, B. Heppner, F. Klauschen et al., Evaluation of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarker in different subtypes of breast cancer treated with neoadjuvant therapy-a metaanalysis of 3771 patients, Proceedings of the 2016 San Antonio Breast Cancer Symposium, 2016.

S. Antonio and . Philadelphia, Cancer Research, vol.77, issue.4, pp.1-09, 2017.

F. Andre, M. V. Dieci, P. Dubsky, C. Sotiriou, G. Curigliano et al., Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer, Clin. Cancer Res, vol.19, issue.1, pp.28-33, 2013.

L. Galluzzi, A. Buque, O. Kepp, L. Zitvogel, and G. Kroemer, Immunological effects of conventional chemotherapy and targeted anticancer agents, Cancer Cell, vol.28, issue.6, pp.690-714, 2015.

M. V. Dieci, Seminars in Cancer Biology, vol.52, pp.16-25, 2018.

S. Demaria, M. D. Volm, R. L. Shapiro, H. T. Yee, R. Oratz et al., Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy, Clin. Cancer Res, vol.7, issue.10, pp.3025-3030, 2001.

R. Gennari, S. Menard, F. Fagnoni, L. Ponchio, M. Scelsi et al., Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2, Clin. Cancer Res, vol.10, issue.17, pp.5650-5655, 2004.

G. Bianchini and L. Gianni, The immune system and response to HER2-targeted treatment in breast cancer, Lancet Oncol, vol.15, issue.2, pp.58-68, 2014.

S. Loibl, L. De-la-pena, V. Nekljudova, D. Zardavas, S. Michiels et al., Phase II, randomized, parallel-cohort study of neoadjuvant buparlisib (BKM120) in combination with trastuzumab and paclitaxel in women with HER2-positive, PIK3CA mutant and PIK3CA wild-type primary breast cancer-NeoPHOEBE, Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium, 2015.

S. Antonio and . Philadelphia, Abstract nr, vol.76, pp.1-14, 2016.

S. C. Leung, T. O. Nielsen, L. Zabaglo, I. Arun, S. S. Badve et al., Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration, NPJ Breast Cancer, vol.2, p.16014, 2016.

G. Minckwitz, A. Schneeweiss, S. Loibl, C. Salat, C. Denkert et al., Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial, Lancet Oncol, vol.15, issue.7, pp.747-756, 2014.

W. F. Symmans, F. Peintinger, C. Hatzis, R. Rajan, H. Kuerer et al., Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy, J. Clin. Oncol, vol.25, issue.28, pp.4414-4422, 2007.

S. Nawaz, A. Heindl, K. Koelble, and Y. Yuan, Beyond immune density: critical role of spatial heterogeneity in estrogen receptor-negative breast cancer, Mod. Pathol, vol.28, issue.12, p.1621, 2015.

W. F. Symmans, C. Wei, R. Gould, X. Yu, Y. Zhang et al., Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype, J. Clin. Oncol, vol.35, issue.10, pp.1049-1060, 2017.

E. Thompson, J. M. Taube, H. Elwood, R. Sharma, A. Meeker et al., The immune microenvironment of breast ductal carcinoma in situ, Mod. Pathol, vol.29, issue.3, pp.249-258, 2016.

M. J. Campbell, F. Baehner, T. O'meara, E. Ojukwu, B. Han et al., Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast, Breast Cancer Res. Treat, 2016.

A. Kim, S. H. Heo, Y. A. Kim, G. Gong, and H. J. Lee, An examination of the local cellular immune response to examples of both ductal carcinoma In situ (DCIS) of the breast and DCIS with microinvasion, with emphasis on tertiary lymphoid structures and tumor infiltrating lymphoctytes, Am. J. Clin. Pathol, vol.146, issue.1, pp.137-144, 2016.

M. Beguinot-cornillon, M. Dauplat, F. Kwiatkowski, G. Lebouedec, L. Tixier et al., Analysis of tumor-infiltrating lymphocytes (TILs) reveals biologically different subgroups of breast ductal carcinoma in situ, Proceedings of the 107th Annual Meeting of the American Association for Cancer Research, vol.76, 2016.

A. Knopfelmacher, J. Fox, Y. Lo, N. Shapiro, and S. Fineberg, Correlation of histopathologic features of ductal carcinoma in situ of the breast with the oncotype DX DCIS score, Mod. Pathol, vol.28, issue.9, pp.1167-1173, 2015.

M. Morita, R. Yamaguchi, M. Tanaka, G. M. Tse, M. Yamaguchi et al., CD8(+) tumor-infiltrating lymphocytes contribute to spontaneous healing in HER2-positive ductal carcinoma in situ, Cancer Med, vol.5, issue.7, pp.1607-1618, 2016.

S. R. Lakhani, I. O. Ellis, S. J. Schnitt, P. H. Tan, M. J. Van-de et al., WHO Classification of Tumours of the Breast, 2012.

M. Morita, R. Yamaguchi, M. Tanaka, G. M. Tse, M. Yamaguchi et al., Two progressive pathways of microinvasive carcinoma: low-grade luminal pathway and high-grade HER2 pathway based on high tumour-infiltrating lymphocytes, J. Clin. Pathol, 2016.

C. R. Gil-del-alcazar, S. J. Huh, M. B. Ekram, A. Trinh, L. L. Liu et al., Immune escape in Breast cancer during In situ to invasive carcinoma transition, Cancer Discov, vol.7, issue.10, pp.1098-1115, 2017.

L. N. Harris, N. Ismaila, L. M. Mcshane, F. Andre, D. E. Collyar et al., Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: american society of clinical oncology clinical practice guideline, J. Clin. Oncol, vol.34, issue.10, pp.1134-1150, 2016.

D. F. Hayes, J. Allen, C. Compton, G. Gustavsen, D. G. Leonard et al., Breaking a vicious cycle, Sci. Transl. Med, vol.5, issue.196, pp.196-202, 2013.

P. Savas, R. Salgado, C. Denkert, C. Sotiriou, P. K. Darcy et al., Clinical relevance of host immunity in breast cancer: from TILs to the clinic, Nat. Rev. Clin. Oncol, vol.13, issue.4, pp.228-241, 2016.

A. S. Hamy, J. Y. Pierga, A. Sabaila, E. Laas, H. Bonsang-kitzis et al., Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer, Ann. Oncol, vol.28, issue.9, pp.2233-2240, 2017.

M. V. Dieci, Seminars in Cancer Biology, vol.52, pp.16-25, 2018.